Emergent BioSolutions Reports Blockbuster Q1 Results, Raises Guidance: What's Going On With The Stock?
Emergent BioSolutions Reports Blockbuster Q1 Results, Raises Guidance: What's Going On With The Stock?
Emergent BioSolutions, Inc. (NYSE:EBS) shares surged higher Thursday after the company announced operational changes to stabilize its financial position and reported first-quarter financial results.
Emergent BioSolutions, Inc.（纽约证券交易所代码：EBS）股价周四飙升，此前该公司宣布了运营调整以稳定其财务状况，并公布了第一季度财务业绩。
The Details:
细节：
Emergent reported quarterly earnings of 59 cents per share, which beat the analyst consensus estimate of losses of 83 cents by 171.08%.
Emergent公布的季度每股收益为59美分，比分析师普遍预期的83美分亏损高出171.08％。
Quarterly sales clocked in at $300.4 million, which beat the analyst consensus estimate of $224.5 million by 33.81% and represents an 82.84% increase from the same period last year.
季度销售额为3.004亿美元，比分析师普遍预期的2.245亿美元高出33.81％，比去年同期增长82.84％。
The company also announced the next phase of its new operational plan that consolidates operations, closes several manufacturing facilities and restructures its enterprise workforce to improve its performance and profitability.
该公司还宣布了其新运营计划的下一阶段，该计划将整合业务，关闭多个制造设施并重组企业员工队伍，以提高其业绩和盈利能力。
Emergent will shut down both its Baltimore-Bayview Drug Substance manufacturing facility and Rockville, Maryland Drug Product facility. The company will also reduce its workforce by 300 employees across all areas of the company, and eliminate approximately 85 positions that are currently vacant.
Emergent将关闭其巴尔的摩-湾景药物制造工厂和马里兰州罗克维尔的药品工厂。该公司还将在公司所有领域裁员300人，并裁撤目前空缺的大约85个职位。
The company expects savings of approximately $80 million when fully implemented. Costs associated with the restructuring plan are estimated to be approximately $18 million to $21 million and are expected to be primarily incurred in the second half of 2024.
该公司预计，全面实施后将节省约8000万美元。与重组计划相关的成本估计约为1,800万至2,100万美元，预计将主要在2024年下半年产生。
Emergent raised its revenue guidance for 2024 to between $1 billion and $1.1 billion.
Emergent将其2024年的收入预期提高至10亿至11亿美元之间。
Related News: Enovix Stock Soars On Blockbuster Q1 Sales
相关新闻： Enovix 股价因第一季度销量大涨而飙升
EBS Stock Prediction 2024:
2024 年 EBS 股票预测：
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
华尔街内外的股票研究分析师通常使用收益增长和基础研究作为估值和预测的一种形式。但是，许多交易者将技术分析作为形成股价走势预测模型的一种方式。
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Emergent BioSolutions, an investor could make an assessment about a stock's long term prospects using a moving average and trend line.
一些投资者通过趋势来帮助预测他们认为股票在未来某个时刻的交易走向。从Emergent BioSolutions来看，投资者可以使用移动平均线和趋势线对股票的长期前景进行评估。
If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Emergent BioSolutions, the 200-day moving average sits at $3.04, according to Benzinga Pro, which is below the current price of $3.99. For more on charts and trend lines, see a description here.
如果他们认为股票将保持在移动平均线上方（许多人认为这是一个看涨信号），他们可以使用趋势线将这种趋势推断到未来。根据Benzinga Pro的数据，Emergent BioSolutions的200天移动平均线为3.04美元，低于目前的3.99美元。有关图表和趋势线的更多信息，请参阅此处的描述。
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
交易者认为，当股票高于其移动平均线时，这是一个普遍看涨的信号，而当它跌破移动平均线时，则是一个更加消极的信号。投资者可以使用趋势线做出有根据的猜测，如果情况保持稳定，股票以后可以在哪里交易。
EBS Price Action: According to Benzinga Pro, Emergent BioSolutions shares closed 70.9% higher at $3.30 on Thursday.
EBS价格走势：根据Benzinga Pro的数据，Emergent BioSolutions股价周四收盘上涨70.9％，至3.30美元。
Image: Gerd Altmann from Pixabay
图片：来自 Pixabay 的 Gerd Altmann